1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Alvotech’s Ustekinumab Passes Safety And Efficacy Milestone

Company Reports Fresh Data For AVT04 Biosimilar Rival To Stelara

 
• By Dave Wallace

Alvotech has announced success in its confirmatory clinical safety and efficacy study for its AVT04 ustekinumab candidate, a proposed biosimilar to Stelara.

Clinical Trial Icon
Alvotech has reported further clinical trial results for its ustekinumab candidate • Source: Shutterstock

Just over a week after announcing positive data from a pharmacokinetic similarity study for its AVT04 ustekinumab candidate, Alvotech has revealed further success in a confirmatory clinical safety and efficacy study for the proposed biosimilar to Stelara.

“Alvotech is the second company to announce positive top-line results from a patient study utilizing a biosimilar candidate to Stelara,” the company noted, following Amgen’s publication of preliminary results from a Phase III study for its ABP 654 candidate earlier this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.